دورية أكاديمية
A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
| العنوان: | A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. |
|---|---|
| المؤلفون: | Roatt BM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil; Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT-DT), Salvador, Brazil., Aguiar-Soares RD; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., Reis LE; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., Cardoso JM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., Mathias FA; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., de Brito RC; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., da Silva SM; Laboratório de Bioensaios em Leishmania, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia , Uberlândia, Minas Gerais , Brazil., Gontijo NF; Laboratório de Fisiologia de Insetos Hematófagos, Departamento de Parasitologia, Universidade Federal de Minas Gerais , Belo Horizonte, Minas Gerais , Brazil., Ferreira SA; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto , Ouro Preto, Minas Gerais , Brazil., Valenzuela JG; Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, MD , USA., Corrêa-Oliveira R; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil; Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT-DT), Salvador, Brazil., Giunchetti RC; Laboratório de Biologia das Interações Celulares, Departamento de Morfologia, Universidade Federal de Minas Gerais , Belo Horizonte, Minas Gerais , Brazil., Reis AB; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil; Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT-DT), Salvador, Brazil. |
| المصدر: | Frontiers in immunology [Front Immunol] 2017 Mar 07; Vol. 8, pp. 217. Date of Electronic Publication: 2017 Mar 07 (Print Publication: 2017). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Print ISSN: 1664-3224 (Print) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Herein, we evaluated the treatment strategy employing a therapeutic heterologous vaccine composed of antigens of Leishmania braziliensis associated with MPL adjuvant (LBMPL vaccine) for visceral leishmaniasis (VL) in symptomatic dogs naturally infected by Leishmania infantum . Sixteen dogs received immunotherapy with MPL adjuvant ( n = 6) or with a vaccine composed of antigens of L. braziliensis associated with MPL (LBMPL vaccine therapy, n = 10). Dogs were submitted to an immunotherapeutic scheme consisting of 3 series composed of 10 subcutaneous doses with 10-day interval between each series. The animals were evaluated before (T0) and 90 days after treatment (T90) for their biochemical/hematological, immunological, clinical, and parasitological variables. Our major results showed that the vaccine therapy with LBMPL was able to restore and normalize main biochemical (urea, AST, ALP, and bilirubin) and hematological (erythrocytes, hemoglobin, hematocrit, and platelets) parameters. In addition, in an ex vivo analysis using flow cytometry, dogs treated with LBMPL vaccine showed increased CD3 + T lymphocytes and their subpopulations (TCD4 + and TCD8 + ), reduction of CD21 + B lymphocytes, increased NK cells (CD5 - CD16 + ) and CD14 + monocytes. Under in vitro conditions, the animals developed a strong antigen-specific lymphoproliferation mainly by TCD4 + and TCD8 + cells; increasing in both TCD4 + IFN-γ + and TCD8 + IFN-γ + as well as reduction of TCD4 + IL-4 + and TCD8 + IL-4 + lymphocytes with an increased production of TNF-α and reduced levels of IL-10. Concerning the clinical signs of canine visceral leishmaniasis, the animals showed an important reduction in the number and intensity of the disease signs; increase body weight as well as reduction of splenomegaly. In addition, the LBMPL immunotherapy also promoted a reduction in parasite burden assessed by real-time PCR. In the bone marrow, we observed seven times less parasites in LBMPL animals compared with MPL group. The skin tissue showed a reduction in parasite burden in LBMPL dogs 127.5 times higher than MPL. As expected, with skin parasite reduction promoted by immunotherapy, we observed a blocking transmission to sand flies in LBMPL dogs with only three positive dogs after xenodiagnosis. The results obtained in this study highlighted the strong potential for the use of this heterologous vaccine therapy as an important strategy for VL treatment. |
| References: | Exp Parasitol. 2011 Nov;129(3):234-9. (PMID: 21864530) Mem Inst Oswaldo Cruz. 2004 Feb;99(1):57-62. (PMID: 15057348) Immunobiology. 2001 Dec;204(5):659-66. (PMID: 11846231) Antimicrob Agents Chemother. 2012 Jun;56(6):2858-67. (PMID: 22411610) N Engl J Med. 1990 Jan 4;322(1):16-21. (PMID: 2104665) Parasit Vectors. 2014 Feb 07;7:61. (PMID: 24507702) Vaccine. 2008 Jul 23;26(31):3922-31. (PMID: 18555567) PLoS One. 2012;7(11):e49780. (PMID: 23189161) Vaccine. 2008 Mar 17;26(12):1585-94. (PMID: 18328956) J Glob Infect Dis. 2010 May;2(2):167-76. (PMID: 20606973) Vet Immunol Immunopathol. 2009 Apr 15;128(4):349-58. (PMID: 19124159) Vaccine. 2004 Jun 2;22(17-18):2234-43. (PMID: 15149782) Trans R Soc Trop Med Hyg. 2010 Jan;104(1):1-2. (PMID: 19712953) Vaccine. 2007 Nov 1;25(44):7674-86. (PMID: 17913311) Vet Rec. 2014 Jul 12;175(2):42-4. (PMID: 25013197) Trends Parasitol. 2010 Jul;26(7):341-9. (PMID: 20488751) Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):188-93. (PMID: 20464151) Eur J Immunol. 2004 May;34(5):1433-40. (PMID: 15114677) Exp Parasitol. 2012 Jul;131(3):377-82. (PMID: 22626518) PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3136. (PMID: 25233461) Acta Trop. 2013 Sep;127(3):174-80. (PMID: 23639468) Vet Parasitol. 2014 Oct 15;205(3-4):472-82. (PMID: 25234767) Rev Soc Bras Med Trop. 2013 Mar-Apr;46(2):128-34. (PMID: 23559342) Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):469-72. (PMID: 15259484) Infect Immun. 2002 Nov;70(11):6284-93. (PMID: 12379707) Lancet. 1987 Feb 21;1(8530):401-5. (PMID: 2880213) Clin Microbiol Rev. 2006 Jan;19(1):111-26. (PMID: 16418526) Antimicrob Agents Chemother. 2015 Aug;59(8):4714-8. (PMID: 26014955) Infect Immun. 1994 Jan;62(1):229-35. (PMID: 8262632) PLoS Negl Trop Dis. 2016 Mar 10;10(3):e0004468. (PMID: 26962865) PLoS One. 2012;7(5):e35671. (PMID: 22693548) Clin Diagn Lab Immunol. 2001 Jul;8(4):828-31. (PMID: 11427436) Insect Mol Biol. 2002 Aug;11(4):315-23. (PMID: 12144696) Vet Immunol Immunopathol. 2009 Apr 15;128(4):418-24. (PMID: 19147234) Res Vet Sci. 2006 Aug;81(1):68-75. (PMID: 16288789) Immunol Cell Biol. 1993 Dec;71 ( Pt 6):583-7. (PMID: 8314285) BMC Infect Dis. 2005 Dec 19;5:113. (PMID: 16364177) Parasitol Int. 2014 Aug;63(4):612-20. (PMID: 24747611) Vet Immunol Immunopathol. 2006 Aug 15;112(3-4):102-16. (PMID: 16621021) PLoS One. 2012;7(7):e40745. (PMID: 22829882) Ann N Y Acad Sci. 2008 Dec;1149:358-60. (PMID: 19120249) Vet Parasitol. 2013 Dec 6;198(3-4):371-81. (PMID: 24129068) Parasit Vectors. 2011 Apr 13;4:52. (PMID: 21489241) Vet Parasitol. 2000 Jun 10;90(1-2):37-45. (PMID: 10828510) Mol Pharm. 2013 Mar 4;10(3):1045-55. (PMID: 23320733) Vaccine. 2016 Jun 3;34(26):2992-5. (PMID: 26973063) Int J Dermatol. 2002 Feb;41(2):73-8. (PMID: 11982640) Vaccine. 2010 Jan 8;28(3):597-603. (PMID: 19800443) PLoS One. 2013 Dec 23;8(12):e82947. (PMID: 24376612) Immunotherapy. 2009 Sep;1(5):765-76. (PMID: 20636022) Vaccine. 2008 Oct 29;26(46):5888-95. (PMID: 18786587) Vaccine. 2010 Apr 26;28(19):3333-40. (PMID: 20206667) Vaccine. 2008 Jan 30;26(5):623-38. (PMID: 18180079) Clin Immunol. 2005 Nov;117(2):182-91. (PMID: 16125466) PLoS Pathog. 2009 May;5(5):e1000441. (PMID: 19461875) Vet Parasitol. 2007 Feb 28;143(3-4):254-9. (PMID: 16996214) World Health Organ Tech Rep Ser. 2010;(949):xii-xiii, 1-186, back cover. (PMID: 21485694) Vet J. 2007 Nov;174(3):636-43. (PMID: 17229582) Rev Soc Bras Med Trop. 2006 Jan-Feb;39(1):14-21. (PMID: 16501760) |
| فهرسة مساهمة: | Keywords: L. infantum; canine visceral leishmaniasis; heterologous vaccine therapy; immune response; immunotherapy |
| تواريخ الأحداث: | Date Created: 20170322 Latest Revision: 20191120 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC5338076 |
| DOI: | 10.3389/fimmu.2017.00217 |
| PMID: | 28321217 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2017.00217 |